Pharmacogenetics of response to antipsychotics in patients with schizophrenia

CNS Drugs

Volumn 25, Issue 11, 2011, Pages 933-969

  Arranz, Maria J ^a   Rivera, Margarita ^a,b   Munro, Janet C ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF GRANADA   (Spain)

^c Optimal Medicine Ltd   (United Kingdom)

Author keywords

Agranulocytosis; Antipsychotics; Clozapine; Movement disorders; Olanzapine; Pharmacogenetics; Pharmacogenomics.Risperidone; Schizophrenia; Weight gain

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); AMINO ACID; AMISULPRIDE; ANKYRIN; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; BROMPERIDOL; CATECHOL METHYLTRANSFERASE; CHLORPROMAZINE; CLOZAPINE; CYTOCHROME P450 2D6; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; EMONAPRIDE; FLUPENTIXOL; HALOPERIDOL; ILOPERIDONE; LEPTIN; MULTIDRUG RESISTANCE PROTEIN 1; NEU DIFFERENTIATION FACTOR; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RGS2 PROTEIN; RISPERIDONE; SEROTONIN; SEROTONIN 2C RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

AGRANULOCYTOSIS; AKATHISIA; ALLELE; BRADYKINESIA; CLINICAL EVALUATION; DEMOGRAPHY; DRUG EFFICACY; DRUG MECHANISM; ENVIRONMENTAL FACTOR; ETHNIC DIFFERENCE; EXTRAPYRAMIDAL SYMPTOM; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HLA SYSTEM; HUMAN; METABOLIC SYNDROME X; MONOTHERAPY; OBESITY; OUTCOME ASSESSMENT; PHARMACOGENETICS; PHARMACOGENOMICS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RIGIDITY; SCHIZOPHRENIA; SIDE EFFECT; TARDIVE DYSKINESIA; TREATMENT RESPONSE; TREMOR; WEIGHT GAIN;

EID: 80555145254     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11595380-000000000-00000     Document Type: Review

References (300)

1. Kay SR, Opler LA, Lindenmayer JP. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res 1988 Jan; 23 (1): 99-110
2. Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord 2006 May; 21 (5): 589-98 (Pubitemid 43792739)
3. Waddington JL, Youssef HA. The expression of schizophrenia, affective disorder and vulnerability to tardive dyskinesia in an extensive pedigree. Br J Psychiatry 1988 Sep; 153: 376-81
4. Vojvoda D, Grimmell K, Sernyak M. Monozygotic twins concordant for response to clozapine [letter]. Lancet 1996; 347 (8993): 61 (Pubitemid 26012429)
5. Horacek J, Libiger J, Hoschl C, et al. Clozapine-induced concordant agranulocytosis in monozygotic twins. Int J Psychiatry Clin Pract 2001; 5 (1): 71-3 (Pubitemid 32410493)
6. Muller DJ, Schulze TG, Knapp M, et al. Familial occurrence of tardive dyskinesia. Acta Psychiatr Scand 2001 Nov; 104 (5): 375-9 (Pubitemid 34280554)
7. Mata I, Madoz V, Arranz MJ, et al. Olanzapine: concordant response in monozygotic twins with schizophrenia [letter]. Br J Psychiatry 2001 Jan; 178 (1): 86 (Pubitemid 32055658)
8. Theisen FM, Gebhardt S, Haberhausen M, et al. Clozapine-induced weight gain: a study in monozygotic twins and same-sex sib pairs. Psychiatr Genet 2005 Dec; 15 (4): 285-9 (Pubitemid 44491467)
9. Wehmeier PM, Gebhardt S, Schmidtke J, et al. Clozapine: weight gain in a pair of monozygotic twins concordant for schizophrenia and mild mental retardation. Psychiatry Res 2005 Feb 28; 133 (2-3): 273-6 (Pubitemid 40312160)
10. Stauffer VL, Case M, Kinon BJ, et al. Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis. Psychiatry Res 2011 May 15; 187 (1-2): 42-8
11. Schennach-Wolff R, Jager M, Obermeier M, et al. Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders: valid predictors of symptomatic response and remission? World J Biol Psychiatry 2010 Aug; 11 (5): 729-38
12. Giegling I, Drago A, Schafer M, et al. Interaction of haloperidol plasma level and antipsychotic effect in early phases of acute psychosis treatment. J Psychiatr Res 2010 Jun; 44 (8): 487-92
13. Lipkovich IA, Deberdt W, Csernansky JG, et al. Defining "good" and "poor" outcomes in patients with schizophrenia or schizoaffective disorder: a multidimensional data-driven approach. Psychiatry Res 2009 Dec 30; 170 (2-3): 161-7
14. Jager M, SchmaussM, Laux G, et al. Early improvement as a predictor of remission and response in schizophrenia: rasults from a naturalistic study. Eur Psychiatry 2009 Dec; 24 (8): 501-6
15. Lin CH, Chou LS, Lin CH, et al. Early prediction of clinical response in schizophrenia patients receiving the atypical antipsychotic zotepine. J Clin Psychiatry 2007 Oct; 68 (10): 1522-7
16. Leucht S, Busch R, Kissling W, et al. Early prediction of antipsychotic nonresponse among patients with schizophrenia. J Clin Psychiatry 2007 Mar; 68 (3): 352-60 (Pubitemid 46506798)
17. Brousse G, Meary A, Blanc O, et al. Clinical predictors of response to olanzapine or risperidone during acute episode of schizophrenia. Psychiatry Res 2010 Aug 30; 179 (1): 12-8
18. Semiz UB, Cetin M, Basoglu C, et al. Clinical predictors of therapeutic response to clozapine in a sample of Turkish patients with treatment-resistant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007 Aug 15; 31 (6): 1330-6 (Pubitemid 47081323)
19. Lieberman JA, Koreen AR, Chakos M, et al. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry 1996; 57 Suppl. 9: 5-9 (Pubitemid 26327751)
20. Crespo-Facorro B, Pelayo-Teran JM, Perez-Iglesias R, et al. Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables. J Psychiatr Res 2007 Oct; 41 (8): 659-66 (Pubitemid 46509645)
21. Alvarez-Jimenez M, Gleeson JF, Henry LP, et al. Prediction of a single psychotic episode: a 7.5-year, prospective study in first-episode psychosis. Schizophr Res 2011 Feb; 125 (2-3): 236-46
22. Haro JM, Novick D, Suarez D, et al. Predictors of the course of illness in outpatients with schizophrenia: a prospective three year study. Prog Neuropsychopharmacol Biol Psychiatry 2008 Jul 1; 32 (5): 1287-92
23. Gunduz-Bruce H, McMeniman M, Robinson DG, et al. Duration of untreated psychosis and time to treatment response for delusions and hallucinations. Am J Psychiatry 2005 Oct; 162 (10): 1966-9 (Pubitemid 41428630)
24. Perkins DO, Gu H, Boteva K, et al. Relationship between duration of untreated psychosis and outcome in firstepisode schizophrenia: a critical review and meta-analysis. Am J Psychiatry 2005 Oct; 162 (10): 1785-804 (Pubitemid 41428609)
25. Emsley R, Rabinowitz J, Medori R. Remission in early psychosis: rates, predictors, and clinical and functional outcome correlates. Schizophr Res 2007 Jan; 89 (1-3): 129-39 (Pubitemid 44881311)
26. Umbricht DS, Wirshing WC, Wirshing DA, et al. Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia. J Clin Psychiatry 2002 May; 63 (5): 420-4 (Pubitemid 34507220)
27. Kinon BJ, Kane JM, Chakos M, et al. Possible predictors of neuroleptic-resistant schizophrenic relapse: influence of negative symptoms and acute extrapyramidal side effects. Psychopharmacol Bull 1993; 29 (3): 365-9 (Pubitemid 24001304)
28. Lieberman JA. Prediction of outcome in first-episode schizophrenia. J Clin Psychiatry 1993 Mar; 54 Suppl.: 13-7 (Pubitemid 23121851)
29. Perkins D, Lieberman J, Gu H, et al. Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. Br J Psychiatry 2004 Jul; 185: 18-24 (Pubitemid 38951625)
30. Pickar D, Owen Jr RR, Litman RE, et al. Predictors of clozapine response in schizophrenia. J Clin Psychiatry 1994 Sep; 55 Suppl. B: 129-32 (Pubitemid 24353036)
31. Jalenques I, Tauveron I, Albuisson E, et al. Weight gain and clozapine. Encephale 1996 Oct; 22 Spec No 3: 77-9
32. Lane HY, Liu YC, Huang CL, et al. Risperidone-related weight gain: genetic and nongenetic predictors. J Clin Psychopharmacol 2006 Apr; 26 (2): 128-34
33. Calarge CA, Ellingrod VL, Zimmerman B, et al. Leptin gene-2548G/A variants predict risperidone-associated weight gain in children and adolescents. Psychiatr Genet 2009 Dec; 19 (6): 320-7
34. Park YM, Chung YC, Lee SH, et al. Weight gain associated with the alpha2a-adrenergic receptor-1,291 C/G polymorphism and olanzapine treatment. Am J Med Genet B Neuropsychiatr Genet 2006 Jun 5; 141 (4): 394-7
35. Ellingrod VL, Perry PJ, Ringold JC, et al. Weight gain associated with the-759C/T polymorphism of the 5HT2C receptor and olanzapine. Am J Med Genet B Neuropsychiatr Genet 2005 Apr 5; 134 (1): 76-8 (Pubitemid 40411114)
36. Godlewska BR, Olajossy-Hilkesberger L, Ciwoniuk M, et al. Olanzapine-induced weight gain is associated with the-759C/T and-697G/C polymorphisms of the HTR2C gene. Pharmacogenomics J 2009 Aug; 9 (4): 234-41
37. Hermes E,NasrallahH,DavisV, et al. The association between weight change and symptom reduction in the CATIE schizophrenia trial. Schizophr Res 2011May; 128 (1-3): 166-70
38. Spina E, de Leon J.Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 2007 Jan; 100 (1): 4-22 (Pubitemid 46051438)
39. van der WJ, Steijns LS, van Weelden MJ. The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement. Pharmacogenetics 2003 Mar; 13 (3): 169-72 (Pubitemid 36324246)
40. Desai HD, Seabolt J, Jann MW. Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective. CNS Drugs 2001; 15 (6): 469-94 (Pubitemid 32601905)
41. de Leon J, Diaz FJ, Rogers T, et al. A pilot study of plasma caffeine concentrations in a US sample of smoker and nonsmoker volunteers. Prog Neuropsychopharmacol Biol Psychiatry 2003 Feb; 27 (1): 165-71 (Pubitemid 36126659)
42. Spina E, Scordo MG, D'Arrigo C. Metabolic drug interactions with new psychotropic agents. Fundam Clin Pharmacol 2003 Oct; 17 (5): 517-38 (Pubitemid 37215077)
43. Arranz MJ, de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry 2007 Jun 5; 12 (8): 707-47 (Pubitemid 47172693)
44. Robinson DG, Woerner MG, Alvir JM, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 1999 Apr; 156 (4): 544-9 (Pubitemid 29162974)
45. Seeman MV. Gender differences in the prescribing of antipsychotic drugs. Am J Psychiatry 2004 Aug; 161 (8): 1324-33 (Pubitemid 38989084)
46. Yasui-Furukori N, Saito M, Nakagami T, et al. Genderspecific prolactin response to antipsychotic treatments with risperidone and olanzapine and its relationship to drug concentrations in patients with acutely exacerbated schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2010 Apr 16; 34 (3): 537-40
47. Emsley RA, Roberts MC, Rataemane S, et al. Ethnicity and treatment response in schizophrenia: a comparison of 3 ethnic groups. J Clin Psychiatry 2002 Jan; 63 (1): 9-14 (Pubitemid 34113480)
48. Bigos KL, Pollock BG, Coley KC, et al. Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol 2008 Feb; 48 (2): 157-65
49. Frackiewicz EJ, Sramek JJ, Herrera JM, et al. Ethnicity and antipsychotic response. Ann Pharmacother 1997 Nov; 31 (11): 1360-9 (Pubitemid 27498025)
50. Tabatabaee M, Sharifi V, Alaghband-rad J, et al. Acute treatment response and its predictors in patients with firstepisode psychosis in Iran. Australas Psychiatry 2008 Apr; 16 (2): 125-9 (Pubitemid 351404144)
51. Joober R, Rouleau GA, Lal S, et al. Increased prevalence of schizophrenia spectrum disorders in relatives of neuroleptic-nonresponsive schizophrenic patients. Schizophr Res 2005 Sep 1; 77 (1): 35-41 (Pubitemid 40957059)
52. Arranz MJ, Munro J, Osborne S, et al. Difficulties in replication of results. Lancet 2000; 356: 1359-60
53. Woodward ND, Jayathilake K, Meltzer HY. COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia. Schizophr Res 2007 Feb; 90 (1-3): 86-96 (Pubitemid 46177559)
54. Eap CB, Bender S, Jaquenoud SE, et al. Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene. J Clin Psychopharmacol 2004 Apr; 24 (2): 214-9 (Pubitemid 38380846)
55. Xu M, Xing Q, Li S, et al. Pharacogenetic effects of dopamine transporter gene polymorphisms on response to chlorpromazine and clozapine and on extrapyramidal syndrome in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2010 Aug 16; 34 (6): 1026-32
56. Potkin SG, Basile VS, Jin Y, et al. D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine. Mol Psychiatry 2003 Jan; 8 (1): 109-13 (Pubitemid 36188580)
57. Hwang R, Shinkai T,De Luca V, et al. Association study of four dopamine D1 receptor gene polymorphisms and clozapine treatment response. J Psychopharmacol 2007 Sep; 21 (7): 718-27 (Pubitemid 47439830)
58. Hwang R, Shinkai T,De Luca V, et al. Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations. Psychopharmacology (Berl) 2005 Aug; 181 (1): 179-87 (Pubitemid 41440929)
59. Hwang R, Shinkai T, Deluca V, et al. Dopamine D2 receptor gene variants and quantitative measures of positive and negative symptom response following clozapine treatment. Eur Neuropsychopharmacol 2006 May; 16 (4): 248-59
60. Shaikh S, Collier DA, Sham P, et al. Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia. Hum Gen 1996; 97: 714-9 (Pubitemid 26150837)
61. Scharfetter J, Chaudhry HR, Hornik K, et al. Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakistani patients. Eur Neuropsychopharmacol 1999; 10 (1): 17-20
62. Zhao AL, Zhao JP, Zhang YH, et al. Dopamine D4 receptor gene exon III polymorphism and interindividual variation in response to clozapine. Int J Neurosci 2005 Nov; 115 (11): 1539-47
63. Zuo L, Luo X, Krystal JH, et al. The efficacies of clozapine and haloperidol in refractory schizophrenia are related to DTNBP1 variation. Pharmacogenet Genomics 2009 Jun; 19 (6): 437-46
64. Kohlrausch FB, Salatino-Oliveira A, Gama CS, et al. Gprotein gene 825C>T polymorphism is associated with response to clozapine in Brazilian schizophrenics. Pharmacogenomics 2008 Oct; 9 (10): 1429-36
65. Souza RP, Romano-Silva MA, Lieberman JA, et al. Genetic association of the GDNF alpha-receptor genes with schizophrenia and clozapine response. J Psychiatr Res 2010 Aug; 44 (11): 700-6
66. Mancama D, Arranz MJ, Munro J, et al. Investigation of promoter variants of the histamine 1 and 2 receptors in schizophrenia and clozapine response. Neurosci Lett 2002 Nov 29; 333 (3): 207-11 (Pubitemid 35335778)
67. Yu YW, Tsai SJ, Yang KH, et al. Evidence for an association between polymorphism in the serotonin-2A receptor variant (102T/C) and increment of N100 amplitude in schizophrenics treated with clozapine. Neuropsychobiology 2001; 43 (2): 79-82 (Pubitemid 32149730)
68. Arranz MJ, Collier DA, Sodhi M, et al. Association between clozapine response and allelic variation in the 5-HT2A receptor gene. Lancet 1995; 346: 281-2
69. Masellis M, Basile VS, Meltzer HY, et al. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology 1998; 19: 123-32 (Pubitemid 28288438)
70. Arranz MJ, Munro J, Owen MJ, et al. Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine. Mol Psychiatry 1998; 3: 61-6 (Pubitemid 28045186)
71. Arranz MJ, Munro J, Sham P, et al. Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response. Schizophr Res 1998; 32: 93-9 (Pubitemid 28364714)
72. Sodhi M, Arranz MJ, Curtis D, et al. Association between clozapine response and allelic variation in the 5-HT2C receptor gene. Neuroreport 1995; 7: 169-72 (Pubitemid 26077220)
73. Arranz MJ, Munro J, Birkett J, et al. Pharmacogenetic prediction of clozapine response. Lancet 2000; 355: 1615-6 (Pubitemid 30240510)
74. Yu YWY, Tsai S-J, Lin C-H, et al. Serotonin-6 receptor variant (C267T) and clinical response to clozapine. Neuroreport 1999; 10: 1231-3 (Pubitemid 29403700)
75. Kohlrausch FB, Salatino-Oliveira A, Gama CS, et al. Influence of serotonin transporter gene polymorphisms on clozapine response in Brazilian schizophrenics. J Psychiatr Res 2010 Dec; 44 (16): 1158-62
76. Souza RP, De Luca V, Meltzer HY, et al. Schizophrenia severity and clozapine treatment outcome association with oxytocinergic genes. Int J Neuropsychopharmacol 2010 Jul; 13 (6): 793-8
77. Bertolino A, Caforio G, Blasi G, et al. Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am J Psychiatry 2004 Oct; 161 (10): 1798-805 (Pubitemid 39314673)
78. Staddon S, Arranz MJ, Mancama D, et al. Clinical applications of pharmacogenetics in psychiatry. Psychopharmacology (Berl) 2002 Jun; 162 (1): 18-23 (Pubitemid 34639551)
79. Adams DH, Close S, Farmen M, et al. Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder. Hum Psychopharmacol 2008 Mar 4; 23 (4): 267-74 (Pubitemid 351982663)
80. Bishop JR, Ellingrod VL, Moline J, et al. Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment. Schizophr Res 2005 Sep 15; 77 (2-3): 253-60 (Pubitemid 41112218)
81. Bozina N, Medved V, Kuzman MR, et al. Association study of olanzapine-induced weight gain and therapeutic response with SERT gene polymorphisms in female schizophrenic patients. J Psychopharmacol 2007 Sep; 21 (7): 728-34 (Pubitemid 47437910)
82. Bozina N, Kuzman MR, Medved V, et al. Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients. J Psychiatr Res 2008 Jan; 42 (2): 89-97 (Pubitemid 350061252)
83. Houston JP, Adams DH, Kirkwood SC, et al. Neuroreceptor gene polymorphisms and olanzapine depressive symptom response in schizophrenia. J Clin Psychopharmacol 2007 Oct; 27 (5): 520-3 (Pubitemid 47415058)
84. Meary A, Brousse G, Jamain S, et al. Pharmacogenetic study of atypical antipsychotic drug response: involvement of the norepinephrine transporter gene. Am J Med Genet B Neuropsychiatr Genet 2008 Jun 5; 147B (4): 491-4 (Pubitemid 351830809)
85. Ikeda M, Yamanouchi Y, Kinoshita Y, et al. Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia. Pharmacogenomics 2008 Oct; 9 (10): 1437-43
86. Xu MQ, St Clair D, Feng GY, et al. BDNF gene is a genetic risk factor for schizophrenia and is related to the chlorpromazine-induced extrapyramidal syndrome in the Chinese population. Pharmacogenet Genomics 2008 Apr 10; 18 (6): 449-57 (Pubitemid 351769923)
87. Du J, Zhang A, Wang L, et al. Relationship between response to risperidone, plasma concentrations of risperidone and CYP3A4 polymorphisms in schizophrenia patients. J Psychopharmacol 2010 Jul; 24 (7): 1115-20
88. Gupta M, Bhatnagar P, Grover S, et al. Association studies of catechol-O-methyltransferase (COMT) gene with schizophrenia and response to antipsychotic treatment. Pharmacogenomics 2009 Mar; 10 (3): 385-97
89. Fijal BA, Kinon BJ, Kapur S, et al. Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia. Pharmacogenomics J 2009 Oct; 9 (5): 311-8
90. Lane HY, Lee CC, Chang YC, et al. Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function. Int J Neuropsychopharmacol 2004 Dec; 7 (4): 461-70
91. Yamanouchi Y, Iwata N, Suzuki T, et al. Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone. Pharmacogenomics J 2003; 3 (6): 356-61 (Pubitemid 38072174)
92. Xing Q, Qian X, Li H, et al. The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients. Int J Neuropsychopharmacol 2007 Oct; 10 (5): 631-7 (Pubitemid 47517516)
93. Lane HY, Hsu SK, Liu YC, et al. Dopamine D3 receptor Ser9Gly polymorphism and risperidone response. J Clin Psychopharmacol 2005 Feb; 25 (1): 6-11
94. Wang L, Fang C, Zhang A, et al. The-1019 C/G polymorphism of the 5-HT(1)A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients. J Psychopharmacol 2008 Nov; 22 (8): 904-9
95. Lane HY, Chang YC, Chiu CC, et al. Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene. Am J Psychiatry 2002 Sep; 159 (9): 1593-5
96. Kim B, Choi EY, Kim CY, et al. Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting. Hum Psychopharmacol 2008 Jan; 23 (1): 61-7 (Pubitemid 351166069)
97. Liu BC, Zhang J, Wang L, et al. HTR2C promoter polymorphisms are associated with risperidone efficacy in Chinese female patients. Pharmacogenomics 2010 May; 11 (5): 685-92
98. Gu B, Wang L, Zhang AP, et al. Association between a polymorphism of the HTR3A gene and therapeutic response to risperidone treatment in drug-naive Chinese schizophrenia patients. Pharmacogenet Genomics 2008 Aug; 18 (8): 721-7
99. Lane HY, Lin CC, Huang CH, et al. Risperidone response and 5-HT6 receptor gene variance: genetic association analysis with adjustment for nongenetic confounders. Schizophr Res 2004 Mar 1; 67 (1): 63-70
100. Wang L, Yu L, He G, et al. Response of risperidone treatment may be associated with polymorphisms of HTT gene in Chinese schizophrenia patients. Neurosci Lett 2007 Feb 27; 414 (1): 1-4 (Pubitemid 46241633)
101. Xing Q, Gao R, Li H, et al. Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients. Pharmacogenomics 2006 Oct; 7 (7): 987-93 (Pubitemid 44644778)
102. Lane HY, Liu YC, Huang CL, et al. RGS4 polymorphisms predict clinical manifestations and responses to risperidone treatment in patients with schizophrenia. J Clin Psychopharmacol 2008 Feb; 28 (1): 64-8
103. Brockmoller J, Kirchheiner J, Schmider J, et al. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther 2002 Oct; 72 (4): 438-52 (Pubitemid 35178869)
104. Wu S, Xing Q, Gao R, et al. Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients. Neurosci Lett 2005 Mar 7; 376 (1): 1-4 (Pubitemid 40202926)
105. Schafer M, Rujescu D, Giegling I, et al. Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene. Am J Psychiatry 2001 May; 158 (5): 802-4 (Pubitemid 32429852)
106. Kwon JS, Kim E,Kang DH, et al. Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole. Eur Neuropsychopharmacol 2008 Dec; 18 (12): 897-907
107. Shen YC, Chen SF, Chen CH, et al. Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients. J Psychiatr Res 2009 Mar; 43 (6): 600-6
108. Yasui-Furukori N, Saito M, Nakagami T, et al. Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry 2006 Mar; 30 (2): 286-91 (Pubitemid 43288068)
109. Krebs MO, Guillin O, Bourdel MC, et al. Brain derived neurotrophic factor (BDNF) gene variants association with age at onset and therapeutic response in schizophrenia. Mol Psychiatry 2000; 5 (5): 558-62
110. Hamdani N, Tabeze JP, Ramoz N, et al. The CNR1 gene as a pharmacogenetic factor for antipsychotics rather than a susceptibility gene for schizophrenia. Eur Neuropsychopharmacol 2008 Jan; 18 (1): 34-40 (Pubitemid 350218211)
111. Weickert TW, Goldberg TE, Mishara A, et al. Catechol-Omethyltransferase val108/158met genotype predicts working memory response to antipsychotic medications. Biol Psychiatry 2004 Nov 1; 56 (9): 677-82 (Pubitemid 39446850)
112. Anttila S, Illi A, Kampman O, et al. Interaction between NOTCH4 and catechol-O-methyltransferase genotypes in schizophrenia patients with poor response to typical neuroleptics. Pharmacogenetics 2004 May; 14 (5): 303-7 (Pubitemid 38638917)
113. Molero P, Ortuno F, Zalacain M, et al. Clinical involvement of catechol-O-methyltransferase polymorphisms in schizophrenia spectrum disorders: influence on the severity of psychotic symptoms and on the response to neuroleptic treatment. Pharmacogenomics J 2007 Dec; 7 (6): 418-26 (Pubitemid 350187454)
114. Suzuki A, Kondo T, Mihara K, et al. The-141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients. Pharmacogenetics 2001 Aug; 11 (6): 545-50 (Pubitemid 32778231)
115. Vijayan NN, Bhaskaran S, Koshy LV, et al. Association of dopamine receptor polymorphisms with schizophrenia and antipsychotic response in a South Indian population [letter]. Behav Brain Funct 2007; 3: 34
116. Dahmen N, Muller MJ, Germeyer S, et al. Genetic polymorphisms of the dopamine D2 and D3 receptor and neuroleptic drug effects in schizophrenic patients. Schizophr Res 2001 Apr 15; 49 (1-2): 223-5 (Pubitemid 32434328)
117. Szekeres G, Keri S, Juhasz A, et al. Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2004 Jan 1; 124 (1): 1-5 (Pubitemid 38031583)
118. Reynolds GP, Yao Z, Zhang X, et al. Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response. Eur Neuropsychopharmacol 2005 Mar; 15 (2): 143-51 (Pubitemid 40193419)
119. Cohen BM, Ennulat DJ, Centorrino F, et al. Polymorphisms of the dopamine D-4 receptor and response to antipsychotic drugs. Psychopharmacology 1999; 141: 6-10 (Pubitemid 29193288)
120. Reynolds GP, Arranz B, Templeman LA, et al. Effect of 5-HT1A receptor gene polymorphism on negative and depressive symptom response to antipsychotic treatment of drug-naive psychotic patients. Am J Psychiatry 2006 Oct; 163 (10): 1826-9 (Pubitemid 44522494)
121. Joober R, Benkelfat C, Brisebois K, et al. T102C polymorphism in the 5HT2A gene and schizophrenia: relation to phenotype and drug response variability. J Psychiatry Neurosci 1999; 24: 141-6
122. HamdaniN, BonniereM, Ades J, et al. Negative symptoms of schizophrenia could explain discrepant data on the association between the 5-HT2A receptor gene and response to antipsychotics. Neurosci Lett 2005 Mar 22; 377 (1): 69-74 (Pubitemid 40255642)
123. Benmessaoud D, Hamdani N, Boni C, et al. Excess of transmission of the G allele of the-1438A/G polymorphism of the 5-HT2A receptor gene in patients with schizophrenia responsive to antipsychotics. BMC Psychiatry 2008; 8: 40
124. Vazquez-Bourgon J, Arranz MJ, Mata I, et al. Serotonin transporter polymorphisms and early response to antipsychotic treatment in first episode of psychosis. Psychiatry Res 2010 Feb 28; 175 (3): 189-94
125. Joober R, Benkelfat C, Lal S, et al. Association between the methylenetetrahydrofolate reductase 677C/T missense mutation and schizophrenia. Mol Psychiatry 2000; 5: 323-6 (Pubitemid 30438410)
126. Strous RD, Greenbaum L, Kanyas K, et al. Association of the dopamine receptor interacting protein gene, NEF3, with early response to antipsychotic medication. Int J Neuropsychopharmacol 2006 May 31; 1-13
127. Kampman O, Anttila S, Illi A, et al. Neuregulin genotype and medication response in Finnish patients with schizophrenia. Neuroreport 2004 Nov 15; 15 (16): 2517-20 (Pubitemid 39579344)
128. ZaiG, Muller DJ, Volavka J, et al. Family and case-control association study of the tumor necrosis factor-alpha (TNF-alpha) gene with schizophrenia and response to antipsychotic medication. Psychopharmacology (Berl) 2006 Oct; 188 (2): 171-82 (Pubitemid 44371155)
129. Shaikh S, Makoff A, Collier DA, et al. Dopamine D4 receptors: potential therapeutic implications in the treatment of schizophrenia. CNS Drugs 1997; 8: 1-11 (Pubitemid 27292543)
130. Shaikh S, Collier D, Kerwin RW, et al. Dopamine D4 receptor subtypes and response to clozapine [letter]. Lancet 1993 Jan 9; 341 (8837): 116 (Pubitemid 23028144)
131. Rao PA, Pickar D, Gejman PV, et al. Allelic variation in the D4 dopamine receptor (DRD4) gene does not predict response to clozapine. Arch Gen Psychiatry 1994 Nov; 51 (11): 912-7
132. Rietschel M, Naber D, Oberlander H, et al. Efficacy and side-effects of clozapine: testing for association with allelic variation in the dopamine D4 receptor gene. Neuropsychopharmacology 1996 Nov; 15 (5): 491-6 (Pubitemid 26389872)
133. Hwang R, Zai C, Tiwari A, et al. Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant. Pharmacogenomics J 2010 Jun; 10 (3): 200-18
134. Arranz MJ, Collier DA, Munro J, et al. Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine. Neurosci Lett 1996; 217: 177-8 (Pubitemid 26358831)
135. Arranz MJ, Kapur S. Pharmacogenetics in psychiatry: are we ready for widespread clinical use? Schizophr Bull 2008 Nov; 34 (6): 1130-44
136. Nothen MM, Rietschel M, Erdmann J, et al. Genetic variation of the 5-HT2A receptor and response to clozapine. Lancet 1995 Sep 30; 346 (8979): 908-9
137. Rietschel M, Naber D, Fimmers R, et al. Efficacy and sideeffects of clozapine not associated with variation in the 5-HT2C receptor. Neuroreport 1997 May 27; 8 (8): 1999-2003 (Pubitemid 27314324)
138. Malhotra AK, Goldman D, Ozaki N, et al. Clozapine response and the 5HT(2C) Cys(23)Ser polymorphism. Neuroreport 1996; 7 (13): 2100-2 (Pubitemid 26361824)
139. Malhotra AK, Goldman D, Ozaki N, et al. Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine. Am J Psychiatry 1996 Aug; 153 (8): 1092-4 (Pubitemid 26264713)
140. Masellis M, Basile VS, Meltzer HY, et al. Lack of association between the T-C267 serotonin 5-HT6 receptor gene (HTR6) polymorphism and prediction of
141. Masellis M, Paterson AD, Badri F, et al. Genetic variation of 5-HT2A receptor and response to clozapine [letter]. Lancet 1995 Oct 21; 346 (8982): 1108
142. Birkett JT, ArranzMJ, Munro J, et al. Association analysis of the 5-HT5A gene in depression, psychosis and antipsychotic response. Neuroreport 2000 Jun 26; 11 (9): 2017-20 (Pubitemid 30429155)
143. Gutierrez B, Arranz MJ, Huezo-Diaz P, et al. Novel mutations in 5-HT3A and 5-HT3B receptor genes not associated with clozapine response. Schizophr Res 2002 Nov 1; 58 (1): 93-7
144. Arranz MJ, Bolonna AA, Munro J, et al. The serotonin transporter and clozapine response. Mol Psychiatry 2000; 5: 124-30
145. Kaiser R, Tremblay PB, Schmider J, et al. Serotonin transporter polymorphisms: no association with response to antipsychotic treatment, but associations with the schizoparanoid and residual subtypes of schizophrenia. Mol Psychiatry 2001 Mar; 6 (2): 179-85 (Pubitemid 32187868)
146. Bolonna AA, Arranz MJ, Munro J, et al. No influence of adrenergic receptor polymorphisms on schizophrenia and antipsychotic response. Neurosci Lett 2000; 280: 65-8 (Pubitemid 30069575)
147. Bolonna AA, Kerwin RW, Munro J, et al. Polymorphisms in the genes for mGluR types 7 and 8: association studies with schizophrenia. SchizophrRes 2001 Jan 15; 47 (1): 99-103 (Pubitemid 32121775)
148. Tsai SJ, Wang YC, Yu Younger WY, et al. Association analysis of polymorphism in the promoter region of the alpha2a-adrenoceptor gene with schizophrenia and clozapine response. Schizophr Res 2001 Apr 15; 49 (1-2): 53-8
149. Arranz MJ, Dawson E, Shaikh S, et al. Cytochrome P4502D6 genotype does not determine response to clozapine. Br J Clin Pharmacol 1995; 39: 417-20
150. Thomas P, Srivastava V, Singh A, et al. Correlates of response to olanzapine in a North Indian schizophrenia sample. Psychiatry Res 2008 Dec 15; 161 (3): 275-83
151. Itokawa M, Arinami T, Toru M. Advanced research on dopamine signaling to develop drugs for the treatment of mental disorders: Ser311Cys polymorphisms of the dopamine D2-receptor gene and schizophrenia. J Pharmacol Sci 2010 Sep 16; 114 (1): 1-5
152. Xuan J, Zhao X, He G, et al. Effects of the dopamine D3 receptor (DRD3) gene polymorphisms on risperidone response: a pharmacogenetic study. Neuropsychopharmacology 2008 Jan; 33 (2): 305-11 (Pubitemid 350243359)
153. Lencz T, Robinson DG, Xu K, et al. DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. Am J Psychiatry 2006 Mar; 163 (3): 529-31 (Pubitemid 44469398)
154. Zalsman G, Frisch A, Lev-Ran S, et al. DRD4 exon III polymorphism and response to risperidone in Israeli adolescents with schizophrenia: a pilot pharmacogenetic study. Eur Neuropsychopharmacol 2003 May; 13 (3): 183-5 (Pubitemid 36506928)
155. Wei Z, Wang L, Xuan J, et al. Association analysis of serotonin receptor 7 gene (HTR7) and risperidone response in Chinese schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry 2009 Apr 30; 33 (3): 547-51
156. Natesan S, Reckless GE, Barlow KB, et al. Amisulpride the 'atypical' atypical antipsychotic: comparison to haloperidol, risperidone and clozapine. Schizophr Res 2008 Oct; 105 (1-3): 224-35
157. Chen SF, Shen YC, Chen CH. Effects of the DRD3 Ser9Gly polymorphism on aripiprazole efficacy in schizophrenic patients as modified by clinical factors. Prog Neuropsychopharmacol Biol Psychiatry 2009 Apr 30; 33 (3): 470-4
158. Lee HY, Kim DJ, Lee HJ, et al. No association of serotonin transporter polymorphism (5-HTTVNTR and 5-HTTLPR) with characteristics and treatment response to atypical antipsychotic agents in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2009 Mar 17; 33 (2): 276-80
159. Muller DJ, De Luca V, Sicard T, et al. Suggestive association between the C825T polymorphism of the G-protein beta3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia. Eur Neuropsychopharmacol 2005 Oct; 15 (5): 525-31 (Pubitemid 41219624)
160. Gasso P, Mas S, Bernardo M, et al. A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms. Pharmacogenomics J 2009 Dec; 9 (6): 404-10
161. Saiz PA, Susce MT, Clark DA, et al. An investigation of the alpha1A-adrenergic receptor gene and antipsychoticinduced side-effects. Hum Psychopharmacol 2008 Mar; 23 (2): 107-14 (Pubitemid 351359582)
162. Xu MQ, Xing QH, Zheng YL, et al. Association of AKT1 gene polymorphisms with risk of schizophrenia and with response to antipsychotics in the Chinese population. J Clin Psychiatry 2007 Sep; 68 (9): 1358-67
163. Liou YJ, Liao DL, Chen JY, et al. Association analysis of the dopamine D3 receptor gene ser9gly and brain-derived neurotrophic factor gene val66met polymorphisms with antipsychotic-induced persistent tardive dyskinesia and clinical expression in Chinese schizophrenic patients. Neuromolecular Med 2004; 5 (3): 243-51
164. Park SW, Lee JG, Kong BG, et al. Genetic association of BDNF val66met and GSK-3beta-50T/C polymorphisms with tardive dyskinesia. Psychiatry Clin Neurosci 2009 Aug; 63 (4): 433-9
165. Zai CC, Tiwari AK, De Luca V, et al. Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia. Eur Neuropsychopharmacol 2009 May; 19 (5): 317-28
166. Srivastava V, Varma PG, Prasad S, et al. Genetic susceptibility to tardive dyskinesia among schizophrenia subjects: IV. Role of dopaminergic pathway gene polymorphisms. Pharmacogenet Genomics 2006 Feb; 16 (2): 111-7 (Pubitemid 43145679)
167. Herken H, Erdal ME, Boke O, et al. Tardive dyskinesia is not associated with the polymorphisms of 5-HT2A receptor gene, serotonin transporter gene and catechol-omethyltransferase gene. Eur Psychiatry 2003 Mar; 18 (2): 77-81 (Pubitemid 36528527)
168. Lai IC, Wang YC, Lin CC, et al. Negative association between catechol-O-methyltransferase (COMT) gene Val158Met polymorphism and persistent tardive dyskinesia in schizophrenia. J Neural Transm 2005 Aug; 112 (8): 1107-13
169. Matsumoto C, Shinkai T, Hori H, et al. Polymorphisms of dopamine degradation enzyme (COMT and MAO) genes and tardive dyskinesia in patients with schizophrenia. Psychiatry Res 2004 Jun 30; 127 (1-2): 1-7 (Pubitemid 38916861)
170. Lafuente A, Bernardo M, Mas S, et al. Polymorphism of dopamine D2 receptor (TaqIA, TaqIB, and-141C Ins/Del) and dopamine degradation enzyme (COMT G158A, A-278G) genes and extrapyramidal symptoms in patients with schizophrenia and bipolar disorders. Psychiatry Res 2008 Nov 30; 161 (2): 131-41
171. Basile VS, Ozdemir V, Masellis M, et al. A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia. Mol Psychiatry 2000 Jul; 5 (4): 410-7 (Pubitemid 30455955)
172. Tiwari AK, Deshpande SN, Rao AR, et al. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism. Pharmacogenomics J 2005; 5 (1): 60-9 (Pubitemid 40220619)
173. Fu Y, Fan CH, Deng HH, et al. Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients. Acta Pharmacol Sin 2006 Mar; 27 (3): 328-32 (Pubitemid 43357029)
174. Matsumoto C, Ohmori O, Shinkai T, et al. Genetic association analysis of functional polymorphisms in the cytochrome P450 1A2 (CYP1A2) gene with tardive dyskinesia in Japanese patients with schizophrenia. Psychiatr Genet 2004 Dec; 14 (4): 209-13 (Pubitemid 40054347)
175. Tiwari AK, Deshpande SN, Lerer B, et al. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: V. Association of CYP1A2 1545 C T polymorphism. Pharmacogenomics J 2007 Oct; 7 (5): 305-11 (Pubitemid 47484771)
176. Schillevoort I, de Boer A, van der Weide J, et al. Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case-control study. Pharmacogenetics 2002 Apr; 12 (3): 235-40 (Pubitemid 34596788)
177. Tiwari AK, Deshpande SN, Rao AR, et al. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms. Schizophr Res 2005 Jun 1; 75 (1): 21-6 (Pubitemid 40487970)
178. LiouYJ,WangYC, BaiYM, et al.Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychoticinduced persistent tardive dyskinesia in Chinese schizophrenic patients. Neuropsychobiology 2004; 49 (4): 167-73
179. Kakihara S, Yoshimura R, Shinkai K, et al. Prediction of response to risperidone treatment with respect to plasma concentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6. Int Clin Psychopharmacol 2005 Mar; 20 (2): 71-8 (Pubitemid 40354395)
180. de Leon J, Susce MT, Pan RM, et al. Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness. J Clin Psychopharmacol 2005 Oct; 25 (5): 448-56 (Pubitemid 41368367)
181. Scordo MG, Spina E, Romeo P, et al. CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients. Eur J Clin Pharmacol 2000 Dec; 56 (9-10): 679-83 (Pubitemid 32204488)
182. Lohmann PL, Bagli M, Krauss H, et al. CYP2D6 polymorphism and tardive dyskinesia in schizophrenic patients. Pharmacopsychiatry 2003 Mar; 36 (2): 73-8 (Pubitemid 36609513)
183. Inada T, Senoo H, Iijima Y, et al. Cytochrome P450 II D6 gene polymorphisms and the neuroleptic-induced extra-pyramidal symptoms in Japanese schizophrenic patients. Psychiatr Genet 2003 Sep; 13 (3): 163-8 (Pubitemid 37082976)
184. Crescenti A, Mas S, Gasso P, et al. Cyp2d6*3, *4, *5 and *6 polymorphisms and antipsychotic-induced extrapyramidal side-effects in patients receiving antipsychotic therapy. Clin Exp Pharmacol Physiol 2008 Jul; 35 (7): 807-11 (Pubitemid 351725235)
185. Segman RH, Heresco-Levy U, Yakir A, et al. Interactive effect of cytochrome P450 17alpha-hydroxylase and dopamine D3 receptor gene polymorphisms on abnormal involuntary movements in chronic schizophrenia. Biol Psychiatry 2002 Feb 1; 51 (3): 261-3 (Pubitemid 34142638)
186. Dolzan V, Plesnicar BK, Serretti A, et al. Polymorphisms in dopamine receptor DRD1 and DRD2 genes and psychopathological and extrapyramidal symptoms in patients on long-term antipsychotic treatment. Am JMed Genet B Neuropsychiatr Genet 2007 Sep 5; 144B (6): 809-15 (Pubitemid 47417211)
187. Mihara K, Suzuki A, Kondo T, et al. No relationship between Taq1 a polymorphism of dopamine D(2) receptor gene and extrapyramidal adverse effects of selective dopamine D(2) antagonists, bromperidol, and nemonapride in schizophrenia: a preliminary study. Am J Med Genet 2000 Jun 12; 96 (3): 422-4
188. Lattuada E, Cavallaro R, Serretti A, et al. Tardive dyskinesia and DRD2, DRD3, DRD4, 5-HT2A variants in schizophrenia: an association study with repeated assessment. Int J Neuropsychopharmacol 2004 Dec; 7 (4): 489-93 (Pubitemid 39648079)
189. Mihara K, Kondo T, Suzuki A, et al. No relationship between-141C Ins/Del polymorphism in the promoter region of dopamine D2 receptor and extrapyramidal adverse effects of selective dopamine D2 antagonists in schizophrenic patients: a preliminary study. Psychiatry Res 2001 Feb 14; 101 (1): 33-8 (Pubitemid 32167112)
190. Chong SA, Tan EC, Tan CH, et al. Polymorphisms of dopamine receptors and tardive dyskinesia among Chinese patients with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2003 Jan 1; 116 (1): 51-4 (Pubitemid 37063614)
191. Hori H, Ohmori O, Shinkai T, et al. Association between three functional polymorphisms of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia. Am J Med Genet 2001 Dec 8; 105 (8): 774-8 (Pubitemid 33101481)
192. Kaiser R, Tremblay PB, Klufmoller F, et al. Relationship between adverse effects of antipsychotic treatment and dopamine D-2 receptor polymorphisms in patients with schizophrenia. Mol Psychiatry 2002; 7 (7): 695-705 (Pubitemid 34984946)
193. Liou YJ, Lai IC, Liao DL, et al. The human dopamine receptor D2 (DRD2) gene is associated with tardive dyskinesia in patients with schizophrenia. Schizophr Res 2006 Sep; 86 (1-3): 323-5
194. Al Hadithy AF, Wilffert B, Stewart RE, et al. Pharmacogenetics of parkinsonism, rigidity, rest tremor, and bradykinesia in African-Caribbean inpatients: differences in association with dopamine and serotonin receptors. Am J Med Genet B Neuropsychiatr Genet 2008 Sep 5; 147B (6): 890-7
195. Steen VM, Lovlie R, MacEwan T, et al. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol Psychiatry 1997; 2 (2): 139-45 (Pubitemid 27166033)
196. Segman R, Neeman T, Herseco-Levy U, et al. Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 1999; 4: 247-53 (Pubitemid 29292174)
197. Rietschel M, Krauss H, Muller DJ, et al. Dopamine D3 receptor variant and tardive dyskinesia 1. Eur Arch Psychiatry Clin Neurosci 2000; 250 (1): 31-5 (Pubitemid 30326370)
198. Garcia-Barcelo MM, Lam LC, Ungvari GS, et al. Dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients. J Neural Transm 2001; 108 (6): 671-7 (Pubitemid 32662411)
199. Lerer B, Segman RH, Fangerau H, et al. Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 2002 Jul; 27 (1): 105-19 (Pubitemid 34626747)
200. Liao DL, Yeh YC, Chen HM, et al. Association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients. Neuropsychobiology 2001; 44 (2): 95-8
201. Woo SI, Kim JW, Rha E, et al. Association of the Ser9Gly polymorphism in the dopamine D3 receptor gene with tardive dyskinesia in Korean schizophrenics 1. Psychiatry Clin Neurosci 2002 Aug; 56 (4): 469-74
202. Eichhammer P, Albus M, Borrmann-Hassenbach M, et al. Association of dopamine D3-receptor gene variants with neuroleptic induced akathisia in schizophrenic patients: a generalization of Steen's study on DRD3 and tardive dyskinesia. Am J Med Genet 2000; 96 (2): 187-91 (Pubitemid 30180861)
203. Rizos EN, Siafakas N, Katsantoni E, et al. Association of the dopamine D3 receptor Ser9Gly and of the serotonin 2C receptor gene polymorphisms with tardive dyskinesia in Greeks with chronic schizophrenic disorder. Psychiatr Genet 2009 Apr; 19 (2): 106-7
204. Wilffert B, Al Hadithy AF, Sing VJ, et al. The role of dopamine D3, 5-HT2A and 5-HT2C receptor variants as pharmacogenetic determinants in tardive dyskinesia in African-Caribbean patients under chronic antipsychotic treatment: Curacao extrapyramidal syndromes study IX. J Psychopharmacol 2009 Aug; 23 (6): 652-9
205. Mihara K, Kondo T, Higuchi H, et al. Tardive dystonia and genetic polymorphisms of cytochrome P4502D6 and dopamine D2 and D3 receptors: a preliminary finding. Am J Med Genet 2002 Aug 8; 114 (6): 693-5
206. Zai CC, Tiwari AK, Basile V, et al. Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patients. Pharmacogenomics J Jun; 9 (3): 168-74
207. Lafuente A, Bernardo M, Mas S, et al. Dopamine transporter (DAT) genotype (VNTR) and phenotype in extrapyramidal symptoms induced by antipsychotics. Schizophr Res 2007 Feb; 90 (1-3): 115-22 (Pubitemid 46177550)
208. Shinkai T, Muller DJ, De Luca V, et al. Genetic association analysis of the glutathione peroxidase (GPX1) gene polymorphism (Pro197Leu) with tardive dyskinesia. Psychiatry Res 2006 Feb 28; 141 (2): 123-8
209. Tan EC, Chong SA, Mahendran R, et al. Susceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptor. Biol Psychiatry 2001 Jul 15; 50 (2): 144-7 (Pubitemid 32728214)
210. Segman RH, Heresco-Levy U, Finkel B, et al. Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 2001 Mar; 6 (2): 225-9 (Pubitemid 32187875)
211. Lerer B, Segman RH, Tan EC, et al. Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype. Int J Neuropsychopharmacol 2005 Sep; 8 (3): 411-25 (Pubitemid 41002495)
212. Deshpande SN, Varma PG, Semwal P, et al. Serotonin receptor gene polymorphisms and their association with tardive dyskinesia among schizophrenia patients from North India. Psychiatr Genet 2005 Sep; 15 (3): 157-8 (Pubitemid 41231934)
213. Basile VS, Ozdemir V, Masellis M, et al. Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia. Mol Psychiatry 2001 Mar; 6 (2): 230-4 (Pubitemid 32187876)
214. Zhang ZJ, Zhang XB, Sha WW, et al. Association of a polymorphism in the promoter region of the serotonin 5-HT2C receptor gene with tardive dyskinesia in patients with schizophrenia. Mol Psychiatry 2002; 7 (7): 670-1 (Pubitemid 34984941)
215. Segman RH, Heresco-Levy U, Finkel B, et al. Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility. Psychopharmacology (Berl) 2000 Nov; 152 (4): 408-13
216. Rietschel M, Naber D, Fimmers R, et al. Efficacy and sideeffects of clozapine not associated with variation in the 5-HT2C receptor. Neuroreport 1999; 8 (8): 1999-2003 (Pubitemid 27314324)
217. Segman RH, Lerer B. Age and the relationship of dopamine D3, serotonin 2C and serotonin 2A receptor genes to abnormal involuntary movements in chronic schizophrenia. Mol Psychiatry 2002; 7 (2): 137-9 (Pubitemid 34177781)
218. Ohmori O, Shinkai T, Hori H, et al. Genetic association analysis of 5-HT(6) receptor gene polymorphism (267C/T) with tardive dyskinesia. Psychiatry Res 2002 Jun 1; 110 (2): 97-102 (Pubitemid 34607606)
219. Chong SA, Tan EC, Tan CH, et al. Tardive dyskinesia is not associated with the serotonin gene polymorphism (5-HTTLPR) in Chinese. Am JMed Genet 2000 Dec 4; 96 (6): 712-5
220. Kastelic M, Koprivsek J, Plesnicar BK, et al. MDR1 gene polymorphisms and response to acute risperidone treatment. Prog Neuropsychopharmacol Biol Psychiatry 2010 Mar 17; 34 (2): 387-92
221. Zhang Z, Zhang X, Hou G, et al. The increased activity of plasma manganese superoxide dismutase in tardive dyskinesia is unrelated to the Ala-9Val polymorphism. J Psychiatr Res 2002 Sep; 36 (5): 317-24 (Pubitemid 34764056)
222. Pae CU, Kim TS, Patkar AA, et al. Manganese superoxide dismutase (MnSOD: Ala-9Val) gene polymorphism may not be associated with schizophrenia and tardive dyskinesia. Psychiatry Res 2007 Sep 30; 153 (1): 77-81 (Pubitemid 47374823)
223. Liu H, Wang C, Chen PH, et al. Association of the manganese superoxide dismutase gene Ala-9Val polymorphism with clinical phenotypes and tardive dyskinesia in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2010 May 30; 34 (4): 692-6
224. Wang YC, Liou YJ, Liao DL, et al. Association analysis of a neural nitric oxide synthase gene polymorphism and antipsychotics-induced tardive dyskinesia in Chinese schizophrenic patients. J Neural Transm 2004 May; 111 (5): 623-9
225. Shinkai T, Ohmori O, Matsumoto C, et al. Genetic association analysis of neuronal nitric oxide synthase gene polymorphism with tardive dyskinesia. Neuromolecular Med 2004; 5 (2): 163-70
226. Liou YJ, Lai IC, Lin MW, et al. Haplotype analysis of endothelial nitric oxide synthase (NOS3) genetic variants and tardive dyskinesia in patients with schizophrenia. Pharmacogenet Genomics 2006 Mar; 16 (3): 151-7
227. Pae CU, Yu HS, Kim JJ, et al. Quinone oxidoreductase (NQO1) gene polymorphism (609C/T) may be associated with tardive dyskinesia, but not with the development of schizophrenia. Int J Neuropsychopharmacol 2004 Dec; 7 (4): 495-500
228. Liou YJ, Wang YC, Lin CC, et al. Association analysis of NAD(P)Hratioquinone oxidoreductase (NQO1) Pro187-Ser genetic polymorphism and tardive dyskinesia in patients with schizophrenia in Taiwan. Int J Neuropsychopharmacol 2005 Sep; 8 (3): 483-6
229. Greenbaum L, Strous RD, Kanyas K, et al. Association of the RGS2 gene with extrapyramidal symptoms induced by treatment with antipsychotic medication. Pharmacogenet Genomics 2007 Jul; 17 (7): 519-28 (Pubitemid 46905218)
230. Greenbaum L, Smith RC, Rigbi A, et al. Further evidence for association of the RGS2 gene with antipsychoticinduced parkinsonism: protective role of a functional polymorphism in the 30-untranslated region. Pharmacogenomics J 2009 Apr; 9 (2): 103-10
231. Higa M, Ohnuma T, Maeshima H, et al. Association analysis between functional polymorphism of the rs4606 SNP in the RGS2 gene and antipsychotic-induced Parkinsonism in Japanese patients with schizophrenia: results from the Juntendo University Schizophrenia Projects (JUSP). Neurosci Lett 2010 Jan 18; 469 (1): 55-9
232. de Leon J, Susce MT, Pan RM, et al. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 2005 Jan; 66 (1): 15-27
233. Fleeman N, McLeod C, Bagust A, et al. The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation. Health Technol Assess 2010 Jan; 14 (3): 1-157, iii
234. Gasso P, Mas S, Crescenti A, et al. Lack of association between antipsychotic-induced extrapyramidal symptoms and polymorphisms in dopamine metabolism and transport genes. Psychiatry Res 2010 Jan 30; 175 (1-2): 173-5
235. Zai CC, De Luca V, Hwang RW, et al. Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients. Mol Psychiatry 2007; 12 (9): 794-5 (Pubitemid 47347796)
236. Bakker PR, van Harten PN, Van Os J. Antipsychoticinduced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a meta analysis. Schizophr Res 2006 Apr; 83 (2-3): 185-92
237. Srivastava V, Deshpande SN, Nimgaonkar VL, et al. Genetic correlates of olanzapine-induced weight gain in schizophrenia subjects from north India: role of metabolic pathway genes. Pharmacogenomics 2008 Aug; 9 (8): 1055-68
238. Shinkai T, De Luca V, Hwang R, et al. Association study between a functional glutathione S-transferase (GSTP1) gene polymorphism (Ile105Val) and tardive dyskinesia. Neurosci Lett 2005 Nov 11; 388 (2): 116-20 (Pubitemid 41206743)
239. Liu YR, Loh EW, Lan TH, et al. ADRA1A gene is associated with BMI in chronic schizophrenia patients exposed to antipsychotics. Pharmacogenomics J 2010 Feb; 10 (1): 30-9
240. Wang YC, Bai YM, Chen JY, et al. Polymorphism of the adrenergic receptor alpha 2a-1291C>G genetic variation and clozapine-induced weight gain. J Neural Transm 2005 Nov; 112 (11): 1463-8
241. Sickert L, Muller DJ, Tiwari AK, et al. Association of the alpha 2A adrenergic receptor-1291C/G polymorphism and antipsychotic-induced weight gain in European-Americans. Pharmacogenomics 2009 Jul; 10 (7): 1169-76
242. Tsai SJ, Yu YW, Lin CH, et al. Association study of adrenergic beta3 receptor (Trp64Arg) and G-protein beta3 subunit gene (C825T) polymorphisms and weight change during clozapine treatment. Neuropsychobiology 2004; 50 (1): 37-40 (Pubitemid 38721167)
243. Clark D, Skrobot OA, Adebiyi I, et al. Apolipoprotein-E gene variants associated with cardiovascular risk factors in antipsychotic recipients. Eur Psychiatry 2009 Oct; 24 (7): 456-63
244. Zhang XY, Zhou DF, Wu GY, et al. BDNF levels and genotype are associated with antipsychotic-induced weight gain in patients with chronic schizophrenia. Neuropsychopharmacology 2008 Aug; 33 (9): 2200-5 (Pubitemid 351992089)
245. Tiwari AK, Rodgers JB, Sicard M, et al. Association study of polymorphisms in cholecystokinin gene and its receptors with antipsychotic induced weight gain in schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry 2010 Dec 1; 34 (8): 1484-90
246. Tiwari AK, Zai CC, Likhodi O, et al. A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in schizophrenia. Neuropsychopharmacology 2010 May; 35 (6): 1315-24
247. Ellingrod VL, Miller D, Schultz SK, et al. CYP2D6 polymorphisms and atypical antipsychotic weight gain. Psychiatr Genet 2002 Mar; 12 (1): 55-8 (Pubitemid 34274495)
248. Zhang ZJ, Yao ZJ, Zhang XB, et al. No association of antipsychotic agent-induced weight gain with a DA receptor gene polymorphism and therapeutic response. Acta Pharmacol Sin 2003 Mar; 24 (3): 235-40
249. Popp J, Leucht S, Heres S, et al. DRD4 48 bp VNTR but not 5-HT 2C Cys23Ser receptor polymorphism is related to antipsychotic-induced weight gain. Pharmacogenomics J 2009 Feb; 9 (1): 71-7
250. Wang YC, Bai YM, Chen JY, et al. C825T polymorphism in the human G protein beta3 subunit gene is associated with long-term clozapine treatment-induced body weight change in the Chinese population. Pharmacogenet Genomics 2005 Oct; 15 (10): 743-8
251. Bishop JR, Ellingrod VL, Moline J, et al. Pilot study of the G-protein beta3 subunit gene (C825T) polymorphism and clinical response to olanzapine or olanzapine-related weight gain in persons with schizophrenia. Med Sci Monit 2006 Feb; 12 (2): BR47-50 (Pubitemid 43200936)
252. Park YM, Chung YC, Lee SH, et al. G-protein beta3 subunit gene 825C/T polymorphism is not associated with olanzapine-induced weight gain in Korean schizophrenic patients. Psychiatry Investig 2009 Mar; 6 (1): 39-43
253. Hong CJ, Lin CH, Yu YW, et al. Genetic variant of the histamine-1 receptor (glu349asp) and body weight change during clozapine treatment. Psychiatr Genet 2002 Sep; 12 (3): 169-71 (Pubitemid 35316205)
254. Hong CJ, Lin CH, Yu YW, et al. Genetic variants of the serotonin system and weight change during clozapine treatment. Pharmacogenetics 2001 Apr; 11 (3): 265-8
255. Al-Janabi I, Arranz MJ, Blakemore AI, et al. Association study of serotonergic gene variants with antipsychoticinduced adverse reactions. Psychiatr Genet 2009 Dec; 19 (6): 305-11
256. Gunes A, Melkersson KI, Scordo MG, et al. Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine. J Clin Psychopharmacol 2009 Feb; 29 (1): 65-8
257. Reynolds GP, Zhang ZJ, Zhang XB. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 2002 Jun 15; 359 (9323): 2086-7 (Pubitemid 34680975)
258. Tsai SJ, Hong CJ, Yu YW, et al.-759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain [letter]. Lancet 2002 Nov 30; 360 (9347): 1790
259. Basile VS, Masellis M, McIntyre RS, et al. Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. J Clin Psychiatry 2001; 62 Suppl. 23: 45-66 (Pubitemid 32952694)
260. Reynolds GP, Zhang Z, Zhang X. Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain. Am J Psychiatry 2003 Apr; 160 (4): 677-9 (Pubitemid 41079599)
261. Miller DD, Ellingrod VL, Holman TL, et al. Clozapineinduced weight gain associated with the 5-HT2C receptor-759-C/T polymorphism. Am J Med Genet B Neuropsychiatr Genet 2005; 133B (1): 97-100 (Pubitemid 40175624)
262. Templeman LA, Reynolds GP, Arranz B, et al. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genomics 2005 Apr; 15 (4): 195-200 (Pubitemid 40569890)
263. Theisen FM, Hinney A, Bromel T, et al. Lack of association between the-759C/T polymorphism of the 5-HT2C receptor gene and clozapine-induced weight gain among German schizophrenic individuals. Psychiatr Genet 2004 Sep; 14 (3): 139-42 (Pubitemid 39281820)
264. Ryu S, Cho EY, Park T, et al. 759 C/T polymorphism of 5-HT2C receptor gene and early phase weight gain associated with antipsychotic drug treatment. Prog Neuropsychopharmacol Biol Psychiatry 2007 Apr 13; 31 (3): 673-7 (Pubitemid 46467047)
265. Park YM, Cho JH, Kang SG, et al. Lack of association between the-759C/T polymorphism of the 5-HT2C receptor gene and olanzapine-induced weight gain among Korean schizophrenic patients. J Clin Pharm Ther 2008 Feb; 33 (1): 55-60
266. Yevtushenko OO, Cooper SJ, O'Neill R, et al. Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia. Br J Psychiatry 2008 Jun; 192 (6): 424-8 (Pubitemid 351809894)
267. Kuzman MR, Medved V, Bozina N, et al. The influence of 5-HT(2C) and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients. Psychiatry Res 2008 Sep 30; 160 (3): 308-15
268. De Luca V, Mueller DJ, de Bartolomeis A, et al. Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis. Int J Neuropsychopharmacol 2007 Oct; 10 (5): 697-704 (Pubitemid 47517523)
269. Mulder H, Franke B, van der-Beek van der AA, et al. The association between HTR2C polymorphisms and obesity in psychiatric patients using antipsychotics: a cross-sectional study. Pharmacogenomics J 2007 Oct; 7 (5): 318-24 (Pubitemid 47471309)
270. Mulder H, Cohen D, Scheffer H, et al. HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study. J Clin Psychopharmacol 2009 Feb; 29 (1): 16-20
271. Opgen-Rhein C, Brandl EJ, Muller DJ, et al. Association of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German sample. Pharmacogenomics 2010 Jun; 11 (6): 773-80
272. Le HS, Theisen FM, Haberhausen M, et al. Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects? Mol Psychiatry 2009 Mar; 14 (3): 308-17
273. Tiwari AK, Zai CC, Meltzer HY, et al. Association study of polymorphisms in insulin induced gene 2 (INSIG2) with antipsychotic-induced weight gain in European and African-American schizophrenia patients. Hum Psychopharmacol 2010 Apr; 25 (3): 253-9
274. Zhang XY, Tan YL, Zhou DF, et al. Association of clozapine-induced weight gain with a polymorphism in the leptin promoter region in patients with chronic schizophrenia in a Chinese population. J Clin Psychopharmacol 2007 Jun; 27 (3): 246-51 (Pubitemid 46763305)
275. Kang SG, Lee HJ, Park YM, et al. Possible association between the-2548A/G polymorphism of the leptin gene and olanzapine-induced weight gain. Prog Neuropsychopharmacol Biol Psychiatry 2008 Jan 1; 32 (1): 160-3
276. Gregoor JG, van der Weide J, Mulder H, et al. Polymorphisms of the LEP-and LEPR gene and obesity in patients using antipsychotic medication. J Clin Psychopharmacol 2009 Feb; 29 (1): 21-5
277. Ellingrod VL, Miller DD, Taylor SF, et al. Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants. Schizophr Res 2008 Jan; 98 (1-3): 47-54 (Pubitemid 350235903)
278. van Winkel R, Rutten BP, Peerbooms O, et al. MTHFR and risk of metabolic syndrome in patients with schizophrenia. Schizophr Res 2010 Aug; 121 (1-3): 193-8
279. Herken H, Erdal M, Aydin N, et al. The association of olanzapine-induced weight gain with peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism in patients with schizophrenia. DNA Cell Biol 2009 Oct; 28 (10): 515-9
280. Muller DJ, Klempan TA, De Luca V, et al. The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia. Neurosci Lett 2005 May 6; 379 (2): 81-9
281. Musil R, Spellmann I, Riedel M, et al. SNAP-25 gene polymorphisms and weight gain in schizophrenic patients. J Psychiatr Res 2008 Oct; 42 (12): 963-70
282. Wang YC, Bai YM, Chen JY, et al. Genetic association between TNF-alpha-308 G>A polymorphism and longitudinal weight change during clozapine treatment. Hum Psychopharmacol 2010 Jun; 25 (4): 303-9
283. Amar A, Segman RH, Shtrussberg S, et al. An association between clozapine-induced agranulocytosis in schizophrenics and HLA-DQB1*0201. Int J Neuropsychopharmacol 1998; 1: 41-4 (Pubitemid 128538364)
284. Valevski A, Klein T, Gazit E, et al. HLA-B38 and clozapine-induced agranulotycosis in Israeli Jewish schizophrenic patients. Eur J Immunogenet 1998; 25 (1): 11-3 (Pubitemid 28154401)
285. Dettling M, Schaub RT, Mueller-Oerlinghausen B, et al. Further evidence of human leukocyte antigen-encoded susceptibility to clozapine-induced agranulocytosis independent of ancestry. Pharmacogenetics 2001 Mar; 11 (2): 135-41 (Pubitemid 32216124)
286. Athanasiou MC, Dettling M, Cascorbi I, et al. Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis. J Clin Psychiatry 2011 Apr; 72 (4): 458-63
287. Mosyagin I, Dettling M, Roots I, et al. Impact of myeloperoxidase and NADPH-oxidase polymorphisms in druginduced agranulocytosis. J Clin Psychopharmacol 2004 Dec; 24 (6): 613-7 (Pubitemid 39518656)
288. Dettling M, Sachse C, Muller-Oerlinghausen B, et al. Clozapine-induced agranulocytosis and hereditary polymorphisms of clozapine metabolizing enzymes: no association with myeloperoxidase and cytochrome P4502D6. Pharmacopsychiatry 2000 Nov; 33 (6): 218-20
289. Ostrousky O, Meged S, Loewenthal R, et al. NQO2 gene is associated with clozapine-induced agranulocytosis. Tissue Antigens 2003 Dec; 62 (6): 483-91 (Pubitemid 37475996)
290. Turbay D, Lieberman J, Alper CA, et al. Tumor necrosis factor constellation polymorphism and clozapin-induced agranulocytosis in two different ethnic groups. Blood 1997; 89 (11): 4167-74 (Pubitemid 27220966)
291. Chagnon YC, Merette C, Bouchard RH, et al. A genome wide linkage study of obesity as secondary effect of antipsychotics in multigenerational families of eastern Quebec affected by psychoses. Mol Psychiatry 2004 Dec; 9 (12): 1067-74 (Pubitemid 40065451)
292. Inada T, Koga M, Ishiguro H, et al. Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neurolepticinduced, treatment-resistant tardive dyskinesia. Pharmacogenet Genomics 2008 Apr; 18 (4): 317-23 (Pubitemid 351367525)
293. McClay JL, Adkins DE, Aberg K, et al. Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. Mol Psychiatry 2011 Jan; 16 (1): 76-85
294. McClay JL, Adkins DE, Aberg K, et al. Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia. Neuropsychopharmacology 2011 Feb; 36 (3): 616-26
295. Aberg K, Adkins DE, Liu Y, et al. Genome-wide association study of antipsychotic-induced QTc interval prolongation. Pharmacogenomics J. Epub 2010 Oct 5
296. Adkins DE, Aberg K, McClay JL, et al. Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs. Mol Psychiatry 2011 Mar; 16 (3): 321-32
297. Alkelai A, Greenbaum L, Rigbi A, et al. Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients. Psychopharmacology (Berl) 2009 Oct; 206 (3): 491-9
298. Lavedan C, Licamele L, Volpi S, et al. Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study. Mol Psychiatry 2009 Aug; 14 (8): 804-19
299. Volpi S, Heaton C, Mack K, et al. Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia. Mol Psychiatry 2009 Nov; 14 (11): 1024-31
300. Ikeda M, Tomita Y, Mouri A, et al. Identification of novel candidate genes for treatment response to risperidone and susceptibility for schizophrenia: integrated analysis among pharmacogenomics, mouse expression, and genetic case-control association approaches. Biol Psychiatry 2010 Feb 1; 67 (3): 263-9